The CDCN’s Annual “Accelerating Research & Treatment for Castleman Disease,” Working Dinner helps to disseminate cutting edge Castleman disease research
The Castleman Disease Collaborative Network (CDCN) hosted the 11th Annual “Accelerating Research & Treatment for Castleman Disease,” working dinner in-person on December 10, 2022 at the annual American Society of Hematology Meeting in New Orleans, Louisiana. The CDCN was delighted to have this event in-person. We were joined with fellow physicians and researchers from around the globe, who are dedicated to advancing the understanding and treatment of Castleman disease. The event discussed cutting edge research and important issues for patient care.
This event was co-sponsored by the CDCN and EUSA Pharma.
Accepted abstracts are below.
1: Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease
Submitted by: Mateo Sarmiento Bustamante
Abstract Link, Poster Link
2: Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines
Submitted by: Sheila K. Pierson, MS
Abstract Link; Poster Link
3: Serum Proteomics Identifies Interferon Gamma Signaling in Idiopathic Multicentric Castleman Disease
Submitted by: Melanie Mumau, PhD
Abstract Link; Poster Link
4: A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders
Submitted by: Joshua D. Brandstadter, MD, PhD, MSc
Abstract Link
5: Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies
Submitted by: Vibhu Agarwal
Abstract Link
6: Symptom burden and its impact on daily life among patients with idiopathic multicentric Castleman disease (iMCD) – findings from an international iMCD patient survey
Submitted by: Sudipto Mukherjee, MD, PhD, MDH
Poster Link
Sessions: Saturday, December 10, 2022
| [Optional] “Drinks and Data” Poster Session |
| Welcome David Fajgenbaum, MD, MBA, MSc |
| Overview of CD and CDCN Award Presentation David Fajgenbaum, MD, MBA, MSc |
| Treatment of UCD and iMCD Frits van Rhee, MD, PhD, MRCP (UK), FRCPath |
| Discussion Group Session |
| Research update 1: CXCL13 is a predictive biomarker in iMCD Sheila Pierson, MS |
| Research update 2: CXCL13 produced from Tph cells play a crucial role in the pathogenesis of iMCD Kazuyuki Yoshizaki, MD, PhD |
| Q & A |
| Research update 3: Novel insights from Transcriptomics of CD lymph nodes Michael Gonzalez, PhD |
| Discussion Group Session |
| Castleman Disease European Network: A call to action Eric Oksenhendler, MD |
| Closing Remarks David Fajgenbaum, MD, MBA, MSc |
This annual meeting is a tremendous example of the power of the CDCN’s collaborative research approach to defeating Castleman disease
If you missed last year’s CDCN’s “Accelerating Research & Treatment for Castleman Disease,” Virtual Working Dinner you can view the recording of the presentations here.
The last in-person CDCN Annual “Accelerating Research & Treatment for Castleman Disease,” Working Dinner was held during the 2019 ASH Meeting in Orlando Florida from December 7th to December 10th at the Rosen Centre. Research related to Castleman disease was showcased in the first hour of the Working Dinner.